Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312)

Status:

Closed to Accrual

III

Phase

1st

Line of Therapy

Advanced / Metastatic

Disease Stage

Biomarker(s)

N/A

Investigational

Product

Cabozantinib

Tyrosine kinase inhibitor (p.o.)

Treatment Arms

o Experimental: Experimental arm - cabozantinib + atezolizumab

o Active Comparator: Control arm - sorafenib

o Single-Agent Cabozantinib arm